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Background. Treatment failure of chloroquine for P. vivax infections has reached high levels in the eastern provinces of
Indonesia, however, in vitro characterization of chloroquine resistance and its associated molecular profile have yet to be
determined. Methods. Using a modified schizont maturation assay we investigated the in vitro chloroquine susceptibility
profile and molecular polymorphisms of P. vivax isolates collected from Papua, Indonesia, where high levels of clinical
chloroquine treatment failure have been reported, and from Thailand, where chloroquine treatment is generally effective.
Results. The geometric mean chloroquine IC50 for P. vivax isolates from Papua (n = 145) was 312 nM [95%CI: 237–411 nM]
compared to 46.8 nM [95%CI: 34.7–63.1 nM] from Thailand (n = 81); p,0.001. Correlating with the known clinical efficacy of
the area, a cut off for chloroquine resistance was defined as 220nM, a level exceeded in 13.6% (11/81) of Thai isolates and 65%
(94/145) of Papuan isolates; p,0.001. Several sequence polymorphisms in pvcrt-o and pvmdr1, and difference in pvmdr1 copy
number were identified. A Y976F mutation in pvmdr1 was present in 96% (123/128) of Papuan isolates and 25% (17/69) of Thai
isolates; p,0.001. Overall, the geometric mean chloroquine IC50 in isolates with the Y976F mutation was 283 nM [95%CI: 211–
379], compared to 44.5 nM [95%CI: 31.3–63.4] in isolates with the wild type; p, 0.001. Pvmdr1 amplification occurred in 23%
(15/66) of Thai isolates compared to none (0/104) of Indonesian isolates (p,0.001), but was not associated with increased
chloroquine resistance after controlling for geographical location. Conclusions. In vitro susceptibility testing of P. vivax
discriminates between populations with differing levels of clinical efficacy of chloroquine. The pvmdr1 polymorphism at Y976F
may provide a useful tool to highlight areas of emerging chloroquine resistance, although further studies defining its clinical
correlates are needed.
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INTRODUCTION
The burden of malaria caused by Plasmodium vivax has been greatly
under-appreciated both in terms of its clinical spectrum and
incidence of disease [1,2]. P. vivax is the most widely distributed
cause of malaria in the world affecting 40% of the worlds population
and causing between 147–436 million clinical infections each year
[3]. Although associated with less mortality than P falciparum it exerts
a considerable morbidity particularly in children and pregnant
women. Control measures are confounded by two major factors:
firstly, the presence of dormant hypnozoite stages in the liver, which
result in relapse infections weeks after the cure of the initial episode,
and secondly the emergence of chloroquine resistance.
In most of the world chloroquine remains the first line of
treatment for patients with vivax malaria. Not only is it well-
tolerated and affordable, but its long half-life provides protection
from early relapses following treatment. The first cases of
chloroquine resistant P. vivax were reported in 1989 from PNG
[4] and northern Papua (formerly Irian Jaya), Indonesia [5,6,7,8].
Chloroquine monotherapy is now virtually ineffective in Papua
Indonesia [8,9,10] with significant clinical resistance apparent
throughout the Indonesian archipelago [5,11]. More recently
sporadic cases have been reported from Myanmar [12], South
America [13,14], Viet Nam [15], and Turkey [16].
Despite these clinical reports, the global prevalence of
chloroquine resistant P. vivax remains poorly defined. Clinical
studies are difficult to carry out and subject to individual variations
in patient immune status, reinfection and frequent relapses. In vitro
susceptibility assays provide an alternative means of assessing drug
susceptibility of Plasmodium spp. Although these tests have been
well established for P. falciparum, their application in P. vivax has
Academic Editor: Colin Sutherland, London School of Hygiene & Tropical
Medicine, United Kingdom
Received June 27, 2007; Accepted October 5, 2007; Published October 31, 2007
Copyright:  2007 Suwanarusk et al. This is an open-access article distributed
under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the
original author and source are credited.
Funding: The Wellcome Trust (UK) and NHMRC (Australia)
Competing Interests: The authors have declared that no competing interests
exist.
* To whom correspondence should be addressed. E-mail: rnp@menzies.edu.au
. These authors contributed equally to this work.
PLoS ONE | www.plosone.org 1 October 2007 | Issue 10 | e1089
been more difficult to develop due to limitations of in vitro culture
methods in this species. Recently several centres have reported
methods for conducting in vitro P. vivax drug susceptibility which
are generally based on the P. falciparum WHO microtest using
quantification of schizont maturation [17,18,19].
The mechanism of P. vivax chloroquine resistance is unknown
and as yet no genetic markers have been identified. In P. falciparum,
polymorphisms in pfcrt and pfmdr1 have been shown to confer
resistance [20,21]. However, no associations have been found
between point mutations in the orthologue genes, pvcrt-o (pvcg10)
and pvmdr1 and the clinical response of vivax malaria to
chloroquine [22,23]. Heterologous systems investigating the effect
of pvcrt-o expression on chloroquine response showed a 2.2-fold
decrease in susceptibility to chloroquine in P. falciparum trans-
formed with pvcrt-o, suggesting a possible role of pvcrt-o in
chloroquine resistant P. vivax [24].
In this study, we investigated the in vitro chloroquine susceptibility
profile and molecular polymorphisms of P. vivax isolates collected
from Papua, Indonesia, where high levels of clinical chloroquine
resistance have been reported [10,25] and from Thailand where
chloroquine treatment is generally effective [26,27].
MATERIALS AND METHODS
Field location and sample collection
Clinical isolates were collected between 2003 and 2006 from two
sites, one in Indonesia and the other in Thailand. Timika, located
in the southern region of Papua Province, Indonesia, has
documented clinical chloroquine resistance with day 28 failure
rates following chloroquine monotherapy exceeding 65% and
16% of patients having early treatment failure [10]. At the second
site at the Shoklo Malaria Research Unit, Mae Sod, Tak Province
on the western border of Thailand, P. vivax remains clinically
sensitive to chloroquine [27].
Patients with symptomatic infections of pure P. vivax presenting
to an outpatient facility were recruited into the study and 5 ml
blood samples collected by venepuncture. After removal of host
white blood cells using a CF11 column, 2 ml of packed infected
Red blood cells (IRBC) were divided as follows: 1 ml was
cryopreserved in glycerolyte, 200 ml spotted onto a filter paper
and 800 ml was used for the in vitro drug susceptibility assay.
Patients were treated with dihydroartemisinin-piperaquine (In-
donesia) or chloroquine (Thailand) according to local guidelines,
but were not followed routinely thereafter.
In vitro drug susceptibility assay
P. vivax susceptibility to chloroquine was measured at both sites using
an identical protocol modified from theWHOmicrotest as described
previously [17]. This method was modified further by reducing the
final haematocrit of the blood media mix (BMM) from 4% to 2%;
and using 200 ml of BMM per well instead of 50 ml. The BMMwere
added to pre-dosed drug plates containing serial concentrations of
chloroquine with doubling dilutions from 2992 nM to 2.92 nM
(Salt). Drug plates were quality assured using P. falciparum clones with
known chloroquine susceptibility: the resistant clones K1 and W2
had median chloroquine IC50s of 120 nM and 470nM respectively
compared to the chloroquine sensitive clones 3D7 and FC27 with
median IC50s of 17 nM and 9 nM.
A traditional candle jar was used to mature the parasites at
37.5uC (25–36 hours) at reduced oxygen concentration. Incuba-
tion was stopped when parasites present had matured to at least
40% schizonts in the drug-free control well. A thick blood film was
made from each well, stained with Giemsa and examined
microscopically. The number of schizonts per 200 asexual stage
parasites was determined and the result for each drug concentra-
tion normalized to the control well. The dose-response data were
analyzed using nonlinear regression analysis (WinNonLin 4.1,
Pharsight Corperation) to obtain the IC50 values. To assess the
effect of verapamil on chloroquine susceptibility, an additional
assay was conducted on 16 Indonesian isolates in which 0.9 mM
verapamil was added to serial dilutions of chloroquine and the
IC50 calculated and compared to that of chloroquine alone.
Malaria DNA preparation and determinantion of
species and hapltotype
Genomic DNA from blood spots and cryopreserved samples was
extracted using QIAamp DNA mini kit (Qiagen). Plasmodium
species were confirmed using multiplex PCR as previously
described [28]. The haplotypes of samples containing a single P.
vivax infection were then determined using three polymorphic
markers, by sequencing pvama1 [29], the number of pvmsp1 bands
after PCR [29] and restriction fragment polymorphism of the
pvmsp3 alpha locus [30].
SNP identification in pvmdr1 and pvcrt-o genes
In order to identify relevant polymorphisms in the pvmdr1 and pvcrt-o
genes in our parasite population 25 Indonesian and 7 Thai P. vivax
isolates (‘‘core’’ samples), were fully sequenced for both genes using
primers listed in Table 1, comparing the sequences to those of the
pvmdr1 (GenBank Acc. No. AY618622) and pvcrt-o (GenBank Acc.
No. AF314649) of the Sal 1, a chloroquine sensitive strain from
Salvador used as a reference strain in this study. All core isolates were
single species, monoclonal infections. PCR conditions were as
follows: a total volume of 50 ml containing 5 ml of 106PCR buffer,
2.5 mM MgCl2, 0.20 mM each dNTP, 1 mM each primer and
1.25 U of AmpliTaq Gold DNA polymerase (Applied Biosystems),
and 1 ml of genomic DNA. PCR was performed under the following
conditions: 95uC for 10 minutes and 40 cycles of at 94uC for
40 seconds, 55uC for 1 minutes and 72uC for 2 minutes. PCR
products were sequenced using the BigDye terminator 3.1 (Applied
Biosystems). Polymorphisms which were identified in the core
samples were then examined in the complete sample set.
Determining pvmdr1 copy number
Pvmdr1 gene copy number was estimated by a novel quantitative
real time SybrGreen PCR assay using the Mx4000 Multiplex
Quantitative PCR system (Stratagene). A single copy gene coding
for P. vivax aldolase (GenBank Acc. No. AF247063), was used as
a reference (normaliser) gene for estimating the pvmdr1 copy
number. Primers rt-pvmdrF, rt-pvmdrR, rt-pvaldoF and rt-
pvaldoR, listed in Table 1, were used to amplify fragments of
the pvmdr1 or the aldolase genes respectively.
Two plasmids, containing cloned fragments of the P. vivax aldolase
gene and either one or two copies of the pvmdr1 fragment, were
constructed de-novo and used as positive controls in every
experiment. PCR reactions were performed in triplicates or
quadruplets and contained 16AB gene ABsoluteTMQPCR SYBRH
Green Mix (Cat. N AB-1166/a), 100 nM of ROX dye (passive
reference dye), 1 ml of DNA template and 75 nM of each primer in
a final volume of 25 ml. Cycling conditions were: 95uC for 15 min;
followed by 40 cycles of 95uC 30 sec, 60uC 1 min and 72uC 30 sec.
Fluorescence data was collected at the end of the annealing and
extension steps 3 times at each and averaged. Following the
amplification cycles, a melting curve analysis was performed to
confirm that the correct products were synthesised. The text report,
containing the threshold cycle (Ct) values for every well was exported
into the Excel program (Microsoft)and analysed.
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The assay was optimised to achieve equal amplification
efficiencies for the pvmdr1 and aldolase gene fragments within
the range of DNA concentrations from 100 ng/ml to 10 pg/ml,
thus the DDCt method (Applied Biosystems User Bulletin N2 (P/N
4303859B) could be used and the pfmdr1 copy number (N) was
calculated as follows: N= 2DDCt6SD, where DDCt= (Ctpvaldo-
Ctpvmdr1 )-(Ct pvaldo cal-Ctpvmdr1 cal). The Ctpvaldo and Ctpvmdr1 used
above are threshold cycle values for the pvmdr1 and aldolase gene
respectively, whereas Ctcal is an average difference between Ctaldo
and Ctpvmdr1 obtained for the positive control containing a single
copy of pvmdr1 and aldolase gene fragments. The SD is a standard
deviation calculated as follows: SD= !(S2pvmdr1+S2pvaldo+S2cal) where
Spvmdr1 and Spvaldo are the standard deviations from the average Ct
calculated for 3 or 4 replicates in the pvmdr1 and pvaldo
amplifications and Scal is an average standard deviation of the
DCt values for the calibrator. Assessment of copy number was
repeated at least twice for all isolates and the repeatability
coefficient determined as 0.30 (viz 95% of repeated estimates of
pvmdr1 copy number were within 0.15 of the first).
Data and sequence analysis
Analysis was performed using SPSS vs 14 for Windows (SPSS
Inc, Chicago, Illinois, USA). The Mann-Whitney U test and
Wilcoxon Signed-Rank test method was used for nonparametric
comparisons, and Student’s t-test (paired and unpaired) or one-
way analysis of variance for parametric comparisons. Proportions
were examined using x2 with Yates’ correction or by Fisher’s
exact test.
A linear regression analysis was used to determine the relationship
between the log-transformed chloroquine in vitro susceptibility and
country or genotype after correcting for duration of assay and initial
percentage of parasites at ring stages, both previously shown to be
confounding factors for in vitro susceptibility (unpublished data). In
Papua, Indonesia the recurrence rate of P. vivax by day 28 following
chloroquine monotherapy in 2004 was 65% [10]. We therefore
defined, a priori, the clinically appropriate cut off for the IC50 as the
35th percentile of isolates from this region.
Sequences were aligned using the Gap4 program, version 4.10
freely available from http://www.mrc-lmb.cam.ac.uk/pubseq/
manual/gap4_windows_2.html).To investigate the relatedness of
the sequences a Clustal C program was used to create the
phylogenetic trees for pvama1, and synonymous SNPs in pvmdr1
and pvcrt-o (ANGIS, http://www.angis.org.au). Unique DNA
sequences described in this paper have been deposited in the
GenBank under the accession No. EF458622 to EF458625.
RESULTS
In vitro chloroquine susceptibility of Indonesian and
Thai Isolates
Between April 2003 and December 2006, 247 isolates were
assayed for in vitro susceptibility of which acceptable chloroquine
susceptibility data could be derived in 226 (91%). Further analysis
was restricted to these isolates (145 from Indonesia and 81 from
Thailand); see figure 1. In total 51% (74/145) of Indonesian
isolates began the assay with more than 40% ring stages prior to
culture, compared to 81% (65/81) of isolates from Thailand;
p,0.001. The time to reach 40% schizonts, and thus the duration
of the assay, was significantly shorter in Indonesian isolates
(26 hours [Range: 22–48]) compared to 36 hours [Range: 21–48]
for isolates from Thailand; p,0.001.
The geometric mean chloroquine IC50 for P. vivax isolates from
Indonesia was 312 nM [95%Confidence Intervals CI: 237–
411 nM] significantly higher than that for Thai isolates
(46.8 nM [95%CI: 34.7–63.1 nM]); p,0.001. After ranking the
226 P. vivax isolates in order of decreasing chloroquine
susceptibility, a continuous non-linear curve of chloroquine IC50
was observed (Figure 2). The 35th percentile for chloroquine IC50
in Indonesian isolates was 220 nM. Using this as an a priori cut-off
for clinically relevant chloroquine resistance, 13.6% (11/81) of
Thai isolates were classified as resistant in vitro.
The chloroquine IC50 values were negatively correlated with
both the duration of assay and the percentage of parasites at
ring stage prior to culture (rs =20.576 and rs =20.496
respectively; p,0.001). However, the difference in chloroquine
IC50 between countries remained after controlling for these
factors independently (Table 2) and in a multivariate compar-
ison; p,0.001.
In total 16 Indonesian isolates were assayed for chloroquine
with and without 0.9 mM verapamil. The median IC50 was not
significantly different: 258 nM [Interquartile Range: 69–950 nM]
for chloroquine plus verapamil compared to 157 nM [IQR: 23–
332 nM] in the chloroquine alone assay; p=0.56.
Table 1. Primers and sequences used to study mutations in
pvmdr1 and pvcrt-o and in the pvmdr1 copy number assay.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
A. pvmdr1 Pvmdr1-1F 59-CTT TTA TGC CTC TCC CCC
Pvmdr1-1Fb 59-AGA TTG TTC TGT AGC CGTT
Pvmdr1-1R 59-GCG TAA GAT GCT AAA ATG AACC
Pvmdr1-2F 59-ATT TAA CCT TTC AGA AAA GCT GT
Pvmdr1-2R 59-CCA CCT GAC AAC TTA GAT GC
Pvmdr1-3F 59-CTG ATA CAA GTG AGG AAG AAC TAC
Pvmdr1-3R 59-ACT ATC CTG GTC AAA AAA GC
Pvmdr1-4F 59-CCC TCT ACA TCT TAG TCA TCG
Pvmdr1-4R 59-TGG TCT GGA CAA GTA TCT AAAA
Pvmdr1-5F 59-GGA AGT TGA TGT CCC TAA AGG
Pvmdr1-5R 59-CCT GGC GCG TCT ACT TAG
B. pvcrt-o pvcg10-1F 59-CGC TGT CGAAGA GCC
pvcg10-1R 59-AGT TTC CCT CTA CAC CCG
pvcg10-2F 59-CGC CCG GTA GAA GC
pvcg10-2R 59-GGT GAG GCG ACA TGG
pvcg10-3F 59-GCT AAG GGC ACA TTT CC
pvcg10-3R 59-GTA GTC CTC AAA AGA CAC ACA TC
pvcg10-4Fa 59-TAT GAA GCA AAT CGC AAC AA
pvcg10-4Fb 59-CTT GAG AGT AAG GCA GCG AA
pvcg10-4R 59-TCA TCC AGA GAG CAA ACT TTC TA
C. pvmdr1 976 Pvmdr976 F 59-GGA TAG TCA TGC CCC AGG ATT G
Pvmdr976 R 59-CAT CAA CTT CCC GGC GTA GC
pvmdr976
internal Internal
59-CGG CTG TAC TGA CCG GAA CGT A
D. pvmdr1
copy number
Pvmdr F 59-CTG ATA CAA GTG AGG AAG AAC TAC G
pvmdrR 59-GTC CAC CTG ACA ACT TAG ATG C
pvaldo F 59-GAC AGT GCC ACC ATC CTT ACC
pvaldoR 59-CCT TCT CAA CAT TCT CCT TCT TTC C
List of primers and their sequences used to amplify and sequence pvmdr1 (A),
pvcrt-o (B) and identification of the pvmdr1 Y976F mutation (C). Primers used to
amplify the fragments of the pvmdr1 and P. vivax aldolase reference gene in the
pvmdr1 copy number assay (D).
doi:10.1371/journal.pone.0001089.t001..
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Polymorphisms in pvmdr1, pvcrt-o and pvama1 in
core samples
Using Sal1 as the reference strain, sequence analysis of 32 core
isolates revealed single nucleotide polymorphisms (SNP) at 5 loci of
pvmdr1, two non-synonymous mutations resulting in amino acid
changes at Y976F and L1076F (Table 3) and three synonymous
SNPs (at codons 493, 908 and 1396). In these core isolates the Y976F
mutation was significantly more prevalent in Indonesian isolates
(96%, 24/25) compared to Thai isolates (43%, 3/7); p=0.004.
One insert and one non-synonymous SNP were found in pvcrt-o
exons, the most prevalent of which was the insertion of the
trinucleotide AAG, coding for amino acid Lysine (K) at amino
acid position 10 in the first exon (see table 3). The insert was found
in 86% (6/7) of Thai isolates and 0% (0/25) Indonesian isolates;
p,0.001.
Analysis of three loci (pvama1, pvmsp1 and pvmsp3) revealed 26
combined haplotypes in the 32 core isolates indicating that the
isolates are of a diverse genetic background. Clustal-c analysis of
partial pvama1 sequences from 89 isolates (Figure 3) showed no
evidence that sequence diversity was less among isolates from
within each field site compared to between locations.
P. vivax chloroquine susceptibility and pvmdr1 and
pvcrt-o polymorphisms
Polymorphisms were assessed for the pvmdr1 SNP at codon 976 in an
additional 165 isolates with in vitro susceptibility data and for the pvcrt-
o insertion at amino acid position 10 in an additional 55 isolates
(Figure 1). After combining these with the core isolates the Y976F
allele was found in 96.1% (123/128) of Indonesian isolates compared
to 25% (17/69) of Thai isolates (p,0.001). Overall, the geometric
mean chloroquine IC50 in isolates with the Y976F mutation was
283 nM [95%CI: 211–379], significantly higher than that in isolates
with the wild type allele (geometric mean=44.5 nM [95%CI: 31.3–
63.4]; p, 0.001). In Thailand, isolates with the Y976F mutation had
a mean IC50 of 65.6 nM [95%CI: 29.9–144] compared to 39.0 nM
[95%CI: 27.8–54.8] in those with the wild type allele (p=0.008, after
controlling for assay duration and percentage of rings pre
incubation). The trend was similar in Indonesian isolates, however
the proportion of Y976F mutation almost reached fixation and thus
prohibited analysis of the correlation between the polymorphism and
the phenotype (see figure 4).
The pvcrt-o AAG insertion occurred in 76% (31/41) of Thai
isolates, but only 2.2% (1/46) of the Indonesian isolates (p,0.001).
Overall the pvcrt-o AAG insertion was associated with a significant
reduction in chloroquine IC50, (geometric mean 47.6 nM
[95%CI: 29.7–76.1] vs 261 nM [95%CI: 172–396]; p,0.001).
After stratifying by geographical location, the AAG insertion of
pvcrt-o was not linked to the pvmdr1 Y976F mutation and was not
significantly associated with reduced chloroquine IC50.
P. vivax chloroquine susceptibility and pvmdr1 copy
number
The pvmdr1 copy number was successfully quantified in 86% (170/
198) of isolates tested. In total 23% (15/66) of isolates from
Thailand had an increased pvmdr1 copy number (13 with 2 copies
and two with 3 copies) and none (0/104) from Indonesia;
p,0.001. In Thailand all (15/15) of the isolates with increased
copy number were wild type at 976, compared to 67% (34/51) of
those with a single copy number of pvmdr1 (p = 0.007). Although
isolates with increased pvmdr1 copy number had significantly lower
chloroquine IC50s (geometric mean= 39.6 [95%CI: 24.5–64.1])
compared to isolates with single copies of pvmdr1 (geometric
mean=184 [95%CI: 137–247]; p,0.001); this was not apparent
after stratification by country.
DISCUSSION
In clinical studies, P. vivax remains predominantly sensitive to
chloroquine in Thailand, whereas in Papua, Indonesia high grade
clinical resistance is already established [10,25,26]. In 2004
a chemotherapeutic study at the Papuan field site demonstrated
that 65% of patients failed treatment within 28 days of
chloroquine monotherapy, 16% of whom had early high grade
failures. Treatment guidelines were changed accordingly to an
Artemisinin combination therapy for both P. falciparum and P. vivax
Figure 1. The selection of samples analysed.
doi:10.1371/journal.pone.0001089.g001
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[31], precluding further clinical studies on the use of chloroquine
monotherapy in this region. In the present study we have
continued our analysis of chloroquine resistance P. vivax using an
identical in vitro methodology in both Indonesia and Thailand and
correlating our results with the known data on the clinical efficacy
of chloroquine in these regions. The Indonesian P. vivax isolates
tested had a significantly higher median chloroquine IC50 and
a higher proportion above the resistance threshold compared with
that of Thai isolates.
The determination of chloroquine susceptibility in P. vivax using
the schizont maturation method is more complicated than the same
method in P. falciparum, due to the asynchrony of the vivax parasites
and possible differential responses to the drug by parasites at
different development stages. Patient samples with higher percentage
of trophozoites and late rings require less incubation time to reach
maturation (unpublished data). The decreased susceptibility to
chloroquine in these samples provides a plausible explanation for our
observation of the negative correlations between IC50 and culture
Figure 2. Distribution of isolate chloroquine IC50. 81 Thai (closed diamonds) and 141 Indonesian (open diamonds) P. vivax isolates ranked in order of
increasing chloroquine IC50.
doi:10.1371/journal.pone.0001089.g002
Table 2. In vitro chloroquine sensitivity (nM) of isolates from Thailand and Indonesia.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
N Geometric Mean IC50 95% Confidence Intervals Range P
ALL Indonesia 145 312 237–411 4.6–5637 P,0.001
Thailand 81 46.8 34.7–63.1 6.7–2231
.30 Hours Duration Indonesia 48 113 67.9–188 4.6–3024 P,0.001
Thailand 69 33.2 26.0–42.5 6.7–430
.40% parasites at ring stage prior to culture Indonesia 74 208 139–312 4.6–3506 P,0.001
Thailand 65 33.7 25.8–44.1 6.7–1264
Values given overall and after selecting cultures with greater than 30 hour duration of assay or a starting with more 40% of parasites at ring stage. Criteria for duration
of assay and percentage of rings in initial culture taken from Tasanor et al 2002 [19]
doi:10.1371/journal.pone.0001089.t002..
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duration as well as with percentage of rings at the start of culture.
Although differentiating between these possibilities is difficult, we
attempted to control for these confounding factors by stratifying our
results according to culture duration and the percentage of rings at
the start of culture; the differences in IC50 between isolates from
Indonesia and Thailand remained.
The in vitro cut-off defining clinically relevant chloroquine
resistance has yet to be defined. Using the clinical failure rate
(65%) observed in the same area, we defined this from the 35th
percentile as 220 nM, almost double the 100nM cut-off value for
chloroquine resistance in P. falciparum. However clinical failures may
have included some relapses that occur within the 28 day follow up
period, and the true rate of recrudescence maybe lower. Hence this
threshold is likely to be the minimum value associated with resistance.
The chloroquine IC50 of Thai isolates were significantly lower
than the Indonesian isolates (Geometric mean= 46.8 vs 312 nM),
although the difference was less after controlling for the duration
of assay (33.2 vs 113 nM) or initial stage of parasite prior to culture
(33.7 vs 208 nM). Interestingly 13.6% (11/81) of Thai isolates had
a chloroquine IC50 over 220nM. Although clinical studies in
Thailand in the 1990s have repeatedly demonstrated the
continued efficacy of chloroquine monotherapy for P. vivax
[26,27], our in vitro results raise the possibility that clinically
relevant chloroquine resistance may now be present at low
prevalence along the western border of Thailand. This is
corroborated by a recent clinical study from the Thai-Myanmar
border demonstrating 34% P. vivax recurrence rates within 28 days
of chloroquine monotherapy [32].
Table 3. Mutations in pvmdr1 and pvcrt-o among 32 core Plasmodium vivax isolates from Indonesian and Thailand and the
reference strains SAL1.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Sample Origin Genotype groups Polymorphisms in pvmdr1 and pvcrt-0
pvmdr1 pvcrt-0 exon
Msp1 LP Msp3 RFLP
AMA1
Sequence
Combined
Genotype Copy number Y976F SNP F1076L SNP K10 Insert I43M SNP
SAL 1 Central America a a a a 1 Y F - I
ANV20 Indonesia b a b b 1 F L - I
VI21 Thailand a b c c 1 Y L K I
VI20 Thailand a a d d 1 F L K I
VI32 Thailand a a d d 2 Y L K I
VI5 Thailand a a c e 2 Y L K I
VRP21 Indonesia b a e f 1 F L - I
VI1 Thailand a a f g 1 F L - I
PV14 Thailand b c d h 1 F L K I
VI23 Thailand a a g i 2 Y L K I
VP63 Indonesia b a h j 1 F L - I
FC1010 Indonesia b a i k 1 F L - I
UVT27 Indonesia b a i k 1 F L - I
FC1232 Indonesia b a c l 1 F L - I
VP56 Indonesia b a c l 1 F L - I
FC1108 Indonesia b a c l 1 F L - I
VRP23 Indonesia b a c l 1 F L - I
VP59 Indonesia a a c m 1 F L - I
FC1158 Indonesia a a c m 1 F L - I
ANV15 Indonesia b d c n 1 F L - I
FC1248 Indonesia b d c n 1 F L - I
VRP20 Indonesia a c j o 1 F L - I
UVT22 Indonesia a a i p 1 Y L - I
ANV16 Indonesia c a i q 1 F L - I
FC1083 Indonesia a c k r 1 F L - I
UVT44 Indonesia a a b s 1 F L - I
ANV18 Indonesia c a i t 1 F L - I
ANV12 Indonesia c d l u 1 F L - I
UVT70 Indonesia c a m v 1 F L - I
FC269 Indonesia b d n w 1 F L - I
FC1290 Indonesia a a o x 1 F L - I
FC10122 Indonesia b a l y 1 F L - I
Isolates are grouped and ordered alphabetically according to the combined pvmsp1, pvmsp3 and ama1 genotype. SNP positions and corresponding amino acid
changes relative to the SAL1 reference strain are in bold.
doi:10.1371/journal.pone.0001089.t003..
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Figure 3. Sequence relatedness among P. vivax isolates from different locations according to clustal-c analysis of pvama1 sequence. Stars
indicate Thai isolates.
doi:10.1371/journal.pone.0001089.g003
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The correlation between in vitro susceptibility and clinical
efficacy at our two study sites validates our in vitro susceptibility test
and suggests that the adapted schizont maturation method may be
usefully applied to investigate the emergence of drug resistance in
P. vivax in other locations. Furthermore, the ability to define
parasite susceptibility free from the confounding factors of host
and environment provides a useful framework from which to
investigate putative molecular markers of drug resistance. We used
our carefully defined sample set to test for associations between the
in vitro response to chloroquine and polymorphisms of the
orthologues of two genes (pvmdr1 and pvcrt-o) known to be
important determinants of chloroquine resistance in P. falciparum.
Although previous studies have not established a link between
these genes and chloroquine resistant P. vivax , these generally used
a relatively small number of clinical isolates in which the
phenotypic definition was possibly confounded by patient
immunity, re-infection and relapses [22,23]. Brega et al identified
the pvmdr1 Y976F and 1076 mutation in a small number of Thai
and Indonesian isolates, although in vitro and clinical correlates
were not presented [33].
In the present study we found two polymorphisms which were
correlated with in vitro chloroquine susceptibility: the pvmdr1 Y976F
mutation and an insertion in the 1st exon (amino acid position 10) of
pvcrt-o. Overall both polymorphisms were associated with a significant
increase in chloroquine IC50. In Papua, Indonesia, where the Y976F
mutation has reached fixation and the AAG insertion was almost
absent it was not possible to test the relevance of these markers.
However inThailand, theY976Fmutationwaspresent in25%(17/69)
of isolates and associated with 1.7 fold increase in IC50 to chloroquine.
To rule out the possibility that the polymorphisms were related
to geographical isolation of the samples, we performed phylogeny
analyses to compare the samples from two locations on pvama1,
a marker unrelated to chloroquine pressure. The results did not
show clustering of samples with location. In addition, we analysed
pvmdr1 sequence including all synonymous changes in pvmdr1
which are presumed not to be selected by drug pressure. Again we
did not see clustering of the samples with location. These analyses
suggest that the Y976F is unlikely to be geographically associated
with the Papua location per se, and provide further evidence for its
selection by chloroquine selective pressure.
Notably a small number of isolates with high IC50 values were
observed from both sites in the absence of the 976 mutation, and
vice versa, suggesting that other major molecular determinants are
likely to be involved. However a role of pvmdr1 in modulating
Figure 4. Association between P. vivax chloroquine IC50 and Y976F mutations in pvmdr1. The solid black horizontal lines show the geometric
mean IC50 (nM) of the P. vivax population samples.
doi:10.1371/journal.pone.0001089.g004
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chloroquine susceptibility is supported by the almost ubiquitous
selection of the Y976F allele in Papua, where high grade
chloroquine resistance is known to predominate.
Gene amplification of the pfmdr1 gene has been shown to be
a major determinant of multidrug resistance in P. falciparum.
Furthermore on the Thai-Myanmar border widespread deployment
of mefloquine has been associated with high prevalence of P.
falciparum isolates with increased pfmdr1 copy number and an
associated decrease in susceptibility to mefloquine, quinine,
lumefantrine, halofantrine and the artemisinin derivatives in P.
falciparum [34]. In this study we report that amplification of pvmdr1
copy number occurs in P. vivax in Thailand, but not Papua, where
mefloquine has not been used. Our data raise the prospect of similar
molecular mechanisms of multi drug resistant phenotype as found in
P. falciparum, although further work is needed to confirm this.
In conclusion, using an in vitro susceptibility assay, we have been
able to define a spectrum of chloroquine susceptibility in P. vivax
and discriminate between populations with differing levels of
clinical efficacy following chloroquine monotherapy. Although the
molecular mechanism underlying chloroquine resistance P. vivax
may involve multigenic loci, the pvmdr1 polymorphism at Y976F
may provide a useful tool to monitor the emergence of chloroquine
resistance.
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